Anti-cancer drug prices cut: NPPA enforces 30% trade margin cap on 137 medicines
Synopsis
India's drug pricing authority has capped trade margins at 30% on 137 anti-cancer medicines, triggering MRP cuts of up to 96.45% — with over 650 formulations now cheaper by more than half. The estimated savings for patients: ₹3,541 crore. State Drug Controllers have until 16 November 2026 to report compliance.
Key Takeaways
NPPA has directed strict enforcement of revised prices on 137 non-scheduled anti-cancer drugs effective 9 November 2026 .
A 30 per cent cap on trade margins applies across the full pharmaceutical supply chain — retail, hospitals, stockists, and dealers.
By 9 November , 85 companies had filed revised MRPs for 121 of 137 medicines , covering 1,366 SKUs .
The highest price reduction reported is 96.45 per cent ; more than 650 formulations saw cuts exceeding 50 per cent .
Estimated patient savings stand at ₹3,541 crore , based on 2025–26 sales volumes.
State Drug Controllers must submit Action Taken Reports to NPPA by 16 November 2026 ; violations attract overcharging proceedings under DPCO, 2013 .
The National Pharmaceutical Pricing Authority (NPPA), operating under the Department of Pharmaceuticals, has directed strict enforcement of reduced prices on 137 non-scheduled anti-cancer drugs following the rollout of the Trade Margin Rationalisation (TMR) mechanism, with revised prices having come into effect from 9 November 2026. The directive, issued on 13 November 2026, mandates compliance across the entire pharmaceutical supply chain — from manufacturers to hospital pharmacies — and warns that violations will trigger overcharging proceedings under the Drugs (Prices Control) Order (DPCO), 2013.
How the Price Cuts Were Arrived At
The NPPA had, through an order dated 17 October 2026, brought 137 non-scheduled anti-cancer medicines under the TMR framework, capping trade margins at 30 per cent across the supply chain — covering retail pharmacies, hospital pharmacies, stockists, dealers, and medical institutions alike. By 9 November 2026, 85 pharmaceutical companies had submitted revised Maximum Retail Prices (MRPs) for 121 of the 137 medicines, accounting for 1,366 stock-keeping units (SKUs). The latest revised price lists — incorporating submissions received up to 11 November 2026 — are now available on the NPPA website and the Pharma Sahi Daam app and portal.
Scale of Price Reductions
The magnitude of the price cuts is significant. The highest reported MRP reduction stands at 96.45 per cent, meaning certain formulations are now available at a fraction of their earlier price. More than 650 formulations recorded MRP reductions exceeding 50 per cent, with the largest cluster of reductions falling in the 50–75 per cent range. The 30 per cent cap applies irrespective of dosage form — tablets, injections, or combinations — for all listed medicines.
Estimated Patient Savings
According to official estimates, the cumulative savings for patients are projected at ₹3,541 crore. This figure has been calculated by comparing original and revised MRPs and applying the differential to sales volumes recorded between April 2025 and March 2026, according to official data. This is a substantial financial relief for cancer patients, who frequently bear high out-of-pocket costs for oncology medications not covered under government insurance schemes.
Monitoring Mechanism and Compliance Deadlines
State Drug Controllers (SDCs) have been directed to rigorously monitor compliance by manufacturers, dealers, hospitals, and medical institutions to ensure that lower MRPs are genuinely passed on to patients — not absorbed at intermediary levels in the supply chain. All stakeholders have been asked to prominently display updated price lists at their premises and on their websites. SDCs are required to submit Action Taken Reports to NPPA by 16 November 2026. Patients or consumers who encounter overcharging, medicine shortages, or non-availability can lodge complaints through the Pharma Sahi Daam app/portal, the NPPA helpline, or via email.
What Comes Next
The outstanding 16 of the 137 drugs — for which revised MRPs have not yet been reported — remain under watch. NPPA is expected to pursue compliance from the remaining pharmaceutical companies and may invoke regulatory action against non-compliant entities. This move is part of a broader Centre push to bring essential oncology drugs within the reach of middle- and lower-income patients, who are often disproportionately burdened by cancer treatment costs.
Point of View
541 crore savings figure is striking, but it is a projection built on historical sales volumes — not a guaranteed transfer to patients. The harder challenge is enforcement: trade margin rationalisation works on paper but has historically leaked at the stockist and hospital pharmacy level, where informal markups are difficult to audit. The 16-November deadline for State Drug Controller reports is tight and optimistic given the patchy track record of state-level drug price monitoring in India. The real test of this intervention will come from random retail price checks — not from MRP filings submitted by manufacturers themselves.
NationPress
14 Nov 2026
Frequently Asked Questions
What is Trade Margin Rationalisation for anti-cancer drugs?
Trade Margin Rationalisation (TMR) is a government mechanism that caps the profit margin pharmaceutical companies, stockists, and pharmacies can earn on the sale of specified drugs. For 137 non-scheduled anti-cancer medicines, the NPPA has set this cap at 30 per cent across the supply chain, effective 9 November 2026.
By how much have anti-cancer drug prices been reduced?
Price reductions vary by formulation. The highest reported cut is 96.45 per cent, and more than 650 formulations have seen MRP reductions exceeding 50 per cent. The largest cluster of reductions falls in the 50–75 per cent range.
How much will patients save under this scheme?
Official estimates put cumulative patient savings at ₹3,541 crore. This has been calculated by applying the difference between original and revised MRPs to actual sales volumes recorded between April 2025 and March 2026.
How can a patient report overcharging or non-availability of these drugs?
Complaints can be filed through the Pharma Sahi Daam app or portal, the NPPA helpline, or via email to the authority. State Drug Controllers are also empowered to act on such complaints.
What happens if a chemist or hospital does not comply with the revised prices?
Non-compliance can result in overcharging proceedings under the Drugs (Prices Control) Order (DPCO), 2013. State Drug Controllers are required to monitor compliance and submit Action Taken Reports to NPPA by 16 November 2026.
